COVID-19, a disease caused by SARS-CoV-2 infection, has become a global pandemic. Patients with myasthenia gravis (MG), often treated with immunosuppressants, might be at higher risk of developing COVID-19 and of demonstrating a severe disease course. We aimed to study prevalence and describe features of COVID-19 in MG patients.
COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course
Businaro, Pietro;Vaghi, Gloria;Diamanti, Luca;Arceri, Sebastiano;Bini, Paola;Colombo, Elena;Cosentino, Giuseppe;Alfonsi, Enrico;Costa, Alfredo;Ravaglia, Sabrina;Mallucci, Giulia;Ballante, Elena;Franciotta, Diego;Gastaldi, Matteo
2021-01-01
Abstract
COVID-19, a disease caused by SARS-CoV-2 infection, has become a global pandemic. Patients with myasthenia gravis (MG), often treated with immunosuppressants, might be at higher risk of developing COVID-19 and of demonstrating a severe disease course. We aimed to study prevalence and describe features of COVID-19 in MG patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
